Duvelisib Plus Romidepsin Yields High Results in Relapsed/Refractory Peripheral T-Cell Lymphoma
Cancer Network,
A positive overall response rate was achieved when patients with relapsed/refractory peripheral T-cell lymphoma were treated…
A positive overall response rate was achieved when patients with relapsed/refractory peripheral T-cell lymphoma were treated…
The combination of duvelisib plus romidepsin was shown to be highly active in patients with relapsed/peripheral T-cell lymphoma…